Evidence map›Paper›PMID 32415225›Full record

ArticleBone marrow transplantation2020

Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.

Anna Sureda, Sonja Genadieva Stavrik, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Sascha Dietricht, Peter Dreger, Olivier Hermine, Chara Kyriakou, Stephen Robinson and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 6 countries.

Anna Sureda *Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain. asureda@iconcologia.net.
Sonja Genadieva Stavrik *University Hematology Clinic, Medical faculty, Skopje, Republic of North Macedonia.ORCID http://orcid.org/0000-0003-4252-9984
Ariane BoumendilEBMT, Lymphoma Working party, Paris, France.
Hervé FinelEBMT, Lymphoma Working party, Paris, France.
Irma KhvedelidzeEBMT, Lymphoma Working party, Paris, France.
Sascha DietrichtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Peter DregerDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Olivier HermineDepartment of Clinical Haematology, AP-HP, Necker Hospital, Paris, France.
Chara KyriakouDepartment of Hematology, University College London Hospital, London, UK.
Stephen RobinsonBone Marrow Transplant Unit, University Hospital Bristol, Bristol, UK.
Norbert SchmitzDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Harry C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.
Alina TanaseDepartment of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Silvia MontotoDepartment of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
European Society for Blood and Marrow Transplantation · FRHeidelberg University · DEHôpital Necker-Enfants Malades · FRInstitut d'Investigació Biomédica de Bellvitge · ESInstitutul Clinic Fundeni · ROPHI University Psychiatric Clinic - Skopje · MKSt Bartholomew's Hospital · GBUniversity College Hospital · GBUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indications for autologous (auto-HCT) and allogeneic transplantation (allo-HCT) in relapsed/refractory Hodgkin lymphoma (rrHL) have been long established. The expectation is that long-term outcomes have significantly improved over time with increased experience in these procedures. The objective of this study was to assess whether this is the case and to identify further areas of improvement. A total of 13,639 adult patients receiving an auto-HCT or allo-HCT for rrHL were reported to the European Society for Blood and Marrow Transplantation (EBMT) over a 25-year period. Regarding auto-HCT, recipients are younger, interval between diagnosis and transplant shorter, peripheral blood has become the universal stem cell source and the use of total body irradiation is almost non-existent in recent years. Allo-HCT is currently mostly used as a second transplant; recipients are younger, fitter and less frequently, chemorefractory. Reduced intensity conditioning protocols have vastly replaced myeloablative protocols. Increasing numbers of haplo-HCT have been reported. Both in auto-HCT and allo-HCT, NRM, PFS and OS have significantly improved but relapse remains the main cause of treatment failure. A better selection of patients and improvements in the supportive care has resulted in a reduction in the NRM. Relapse after HCT remains unchanged and further research is needed.

Indexed as

Hematopoietic Stem Cell TransplantationHodgkin DiseaseAdultDisease-Free SurvivalHumansNeoplasm Recurrence, LocalTransplantation Conditioning

Identifiers

PMID32415225
OpenAlexW3024658200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.